Zhenglin He

Dr. Zhenglin He


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2026 in Immunity & Inflammation
Verified
Journal Article
Open access
PDF file
ZHZhenglin He
Zhenglin He
HHHanming Hao
Hanming Hao
BCBaoer Chen
Baoer Chen
XLXuechao Li
Xuechao Li
DMDezhi Mao
Dezhi Mao
GCGuanyu Chen
Guanyu Chen
Osteoarthritis (OA), the leading global cause of joint-related disability, is increasingly viewed as an immune-mediated disorder rather than mere mechanical wear-and-tear. Yet how resident and infiltrating immune cells, inflammatory mediators and dysregulated signaling networks act in concert to perpetuate synovitis, erode cartilage and remodel subchondral bone remains a central enigma. This review dissects the cellular and molecular choreography underlying OA pathology. We detail how macrophages, dendritic cells (DCs), neutrophils, mast cells (MCs), natural killer cells (NK cells), T cells, and B cells orchestrate destructive immune-bone crosstalk within the joint microenvironment. Key inflammatory mediators such as tumor necrosis factor-alpha (TNF-α), transforming growth factor-beta (TGF-β), interleukins (e.g., interleukin (IL)-1β, IL-6), and chemokines sustain this inflammatory loop, further perpetuating inflammation and cartilage damage. Dysregulated signaling pathways, such as nuclear factor-kappa B (NF-κB) and Wingless-type (Wnt)/β-catenin, are coordinated with inflammatory mediators, thereby contributing to the pathophysiology of OA. Beyond mechanism, we critically evaluate cutting-edge therapeutic strategies targeting these osteoimmunological and molecular mechanisms, such as immunomodulatory therapy, mesenchymal stem cell (MSC) therapy and small-molecule pathway inhibitors. Preclinical successes underscore the feasibility of targeting immune-signaling axes to halt or reverse OA progression. By elucidating these mechanisms and therapeutic targets, this review aims to advance the development of disease-modifying therapies and improve outcomes for OA patients.

1 May 2025 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
ZHZhenglin He
Zhenglin He
XZXuepeng Zheng
Xuepeng Zheng
RLRuiqi Liu
Ruiqi Liu
KZKai Zhao
Kai Zhao
DMDezhi Mao
Dezhi Mao
XWXue Wang
Xue Wang
Cervical cancer, a significant public health concern, demands precise and expeditious detection methods to curb the spread of human papillomavirus (HPV). The early detection of cervical cancer remains a critical challenge in developing reliable and efficient screening tools to meet the demand for controlling cervical cancer. Traditional detection techniques are often cumbersome, costly, and inadequate for on-site HPV testing. Nanotechnology, with its unique electrical, chemical, and optical properties, has emerged as a pivotal component in the development of biosensors for rapid and reliable HPV detection. This article provides a comprehensive review of the advancements in cervical cancer detection, encompassing traditional methods, emerging protocols, and novel quantum dots (QDs)-based approaches for detection. The review examines the application of various nanomaterials in electrochemical and photoelectrochemical biosensors for the diagnosis of cervical cancer, with these innovations offering a significant improvement over conventional approach. Furthermore, we detail the synthesis methods of QDs and their properties, illustrate the substantial enhancement in sensor performance achieved through their applications, and elucidate the improvements and challenges associated with these new protocols while highlighting the potential application prospects of novel QDs technology in HPV detection.

1 April 2026 in International Journal of Nanomedicine
Verified
Journal Article
Open access
ZHZhenglin He
Zhenglin He
YCYimeng Chen
Yimeng Chen
KZKai Zhao
Kai Zhao
YJYiping Jiao
Yiping Jiao
YJYishuo Ji
Yishuo Ji
YHYue Hu
Yue Hu
Osteoarthritis (OA) is no longer viewed as a mere “wear-and-tear” disease, but rather as a multifactorial joint failure syndrome driven by cellular senescence, metabolic dysregulation, and low-grade chronic inflammation. These pathological pillars synergistically disrupt cartilage homeostasis, subchondral bone remodeling, and synovial inflammation, collectively fueling disease progression. While conventional therapies offer only symptomatic relief, they fail to reverse or reprogram the underlying pathological microenvironment. Consequently, there is an urgent need to develop disease-modifying interventions that can simultaneously target these pathological pillars. Here, we critically examine how nanomaterial-based platforms—leveraging tailorable surface chemistry, cartilage-penetrating dimensions, and stimuli-responsive cargo release—enable precision targeting of these interconnected mechanisms. We highlight advances in senolytic delivery for senescent cell clearance, redox-modulating nanozymes for metabolic reprogramming, and immunoregulatory strategies for macrophage repolarization, emphasizing designs that transcend passive drug delivery to actively remodel the joint microenvironment. By integrating mechanistic insights with engineering innovation, this review outlines a roadmap for next-generation disease-modifying nanomedicines that promise not merely to slow OA progression, but to restore the biological clock of the joint. We also discuss current translational barriers and propose future directions for personalized OA therapy.

12 February 2026 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
PDF file
YJYishuo Ji
Yishuo Ji
YWYing Wang
Ying Wang
XYXiaowei Yu
Xiaowei Yu
YJYi Jin
Yi Jin
KZKai Zhao
Kai Zhao
ZHZhenglin He
Zhenglin He
Aging and aging-related diseases are increasingly viewed as systemic disorders arising from disrupted inter-organ communication, yet the mechanisms linking local metabolic stress to organism-wide dysfunction remain unclear. The liver occupies a central position in this network, but how hepatic mitochondrial stress is translated into circulating signals that remodel distant tissues is incompletely understood. Here, we synthesize evidence identifying hepatic mitochondria as a systemic signaling hub that integrates metabolic and inflammatory stress and disseminates blood-borne cues during aging. We focus on three major classes of mitochondrial outputs: UPRmt-driven mitokines, including fibroblast growth factor 21 (FGF21) and growth differentiation factor 15 (GDF15); metabolites generated through mitochondrial metabolic reprogramming; and mitochondrial danger signals such as mitochondrial reactive oxygen species (mtROS) and oxidized mitochondrial DNA (mtDNA). These signals act through endocrine, metabolic, and immune pathways to reshape mitochondrial function, inflammation, and energy homeostasis across multiple organs. We further discuss how aging shifts hepatic mitochondrial signaling from adaptive to maladaptive states and emphasize that liver-centered regulation operates within bidirectional networks involving the gut, skeletal muscle, and immune system. Finally, we outline translational challenges and potential strategies for modulating hepatic mitochondrial outputs to restore systemic homeostasis in aging and aging-related diseases.

26 January 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
XLXuechao Li
Xuechao Li
YRYifei Ren
Yifei Ren
SPShenghua Pei
Shenghua Pei
KZKai Zhao
Kai Zhao
GCGuanyu Chen
Guanyu Chen
ZHZhenglin He
Zhenglin He
Oral squamous cell carcinoma (OSCC) is a prevalent and aggressive malignancy with a persistently high mortality rate, largely attributable to therapy resistance and tumor recurrence. This review comprehensively explores the critical interplay between epigenetic dysregulation and the tumor microenvironment (TME) in driving OSCC progression. We detail how key epigenetic mechanisms, including DNA methylation, histone modifications, and non-coding RNAs (ncRNAs), intrinsically transform cancer cells and actively orchestrate pro-tumorigenic TME. These alterations substantially contribute to resistance against conventional therapies. Furthermore, we discuss the therapeutic potential of targeting these pathways using epigenetic drugs (epi-drugs), such as DNA methyltransferase (DNMT) inhibitors and histone deacetylase (HDAC) inhibitors, as well as engineered extracellular vesicles (EVs). The primary objective of this review is to synthesize current knowledge on the epigenetic-TME axis, thereby providing a mechanistic foundation for developing novel therapeutic strategies. We emphasize that rational combinations of epigenetic-targeting agents with conventional treatments or immunotherapy hold significant promise for overcoming drug resistance and improving clinical outcomes in OSCC patients.

8 April 2026 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
PDF file
ZHZhenglin He
Zhenglin He
HHHanming Hao
Hanming Hao
XLXuechao Li
Xuechao Li
YJYishuo Ji
Yishuo Ji
KZKai Zhao
Kai Zhao
XWXue Wang
Xue Wang
Despite significant advances in preventive and early-detection strategies, cervical cancer (CC) continues to pose a substantial clinical burden, especially when confronting the challenge of therapy-resistant or recurrent disease. Long non-coding RNAs (lncRNAs) have emerged as crucial regulators in the development and progression of CC, particularly in mediating resistance to conventional and emerging therapies, including chemotherapy, radiotherapy, and immunotherapy. This review summarizes how specific lncRNAs drive therapeutic resistance through diverse mechanisms such as acting as competitive endogenous RNAs (ceRNAs) to sponge tumor-suppressive microRNAs, and by modulating key signaling pathways like PI3K/Akt and Wnt/β-catenin. Furthermore, we discuss the significant potential of lncRNAs as non-invasive diagnostic and prognostic biomarkers, detectable in liquid biopsies from patient serum or plasma, and as novel therapeutic targets. Advances in targeted strategies have primarily focused on the implementation of precise degradation or interference through antisense oligonucleotides (ASOs) and CRISPR-based systems, highlighting the translational potential of lncRNAs in overcoming refractory therapeutic resistance. Collectively, this review aims to provide a comprehensive overview of the multifaceted roles of lncRNAs in CC therapeutic resistance, offering critical insights that may accelerate the translation of lncRNA-based strategies into clinically actionable interventions to improve patient outcomes in therapy-resistant CC.